Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data

Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, 2026.

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib

Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.
Seeking Alpha

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data

Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...
Nasdaq

Positive Phase 1b Results for I-Mab's Givastomig in Metastatic Gastric Cancer Show 71% Objective Response Rate with Favorable Safety Profile

I-Mab reported positive Phase 1b study results for givastomig in metastatic gastric cancers, highlighting significant efficacy and a favorable safety profile. I-Mab has announced positive results from ...
Hosted on MSN

Kymera Therapeutics soars 35% on positive phase 1 results for oral STAT6 degrader KT-621

Kymera Therapeutics (NASDAQ:KYMR) Monday reported positive Phase 1 results from its healthy volunteer study of KT-621, a first-in-class oral STAT6 degrader, sending shares up +35% in premarket trading ...
Nasdaq

Veru Inc. Announce Positive Topline Safety Data from Phase 2b QUALITY Study of Enobosarm Combined with Semaglutide

Veru's Phase 2b study shows enobosarm combined with semaglutide improves safety, reduces gastrointestinal issues, and promotes fat loss while preserving lean mass. There is a potential risk that the ...